Compare CRSP & CUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | CUZ |
|---|---|---|
| Founded | 2013 | 1958 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.7B |
| IPO Year | 2016 | 1994 |
| Metric | CRSP | CUZ |
|---|---|---|
| Price | $54.47 | $28.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 8 |
| Target Price | ★ $70.29 | $28.00 |
| AVG Volume (30 Days) | 1.7M | ★ 1.7M |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 5.11% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $289,590,000.00 | ★ $993,816,000.00 |
| Revenue This Year | $807.72 | $5.61 |
| Revenue Next Year | $172.52 | $4.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 9169.85 | 16.00 |
| 52 Week Low | $44.12 | $21.03 |
| 52 Week High | $78.48 | $30.57 |
| Indicator | CRSP | CUZ |
|---|---|---|
| Relative Strength Index (RSI) | 55.94 | 60.34 |
| Support Level | $47.48 | $28.03 |
| Resistance Level | $59.61 | $29.62 |
| Average True Range (ATR) | 2.84 | 0.67 |
| MACD | 0.25 | -0.08 |
| Stochastic Oscillator | 54.76 | 62.04 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Cousins Properties Inc is a real estate investment trust principally involved in the ownership, management, and development of properties in the Southern United States. Cousins Properties' real estate portfolio mainly comprises offices and mixed-use developments that encompass both apartment and retail space. Offices make up the vast majority of the portfolio in terms of total square footage. The segments operates in following geographical areas: Atlanta, Austin, Charlotte, Dallas, Phoenix, Tampa, and other markets. The company derives nearly all of its revenue in the form of rental income from its properties, the majority of which comes from its office locations. A diverse set of tenants in the cities of Houston and Atlanta represent the company's key markets.